Alzheimer's disease drug development pipeline: 2024
Alzheimer s & Dementia Translational Research & Clinical Interventions2024Vol. 10(2), pp. e12465–e12465
Citations Over TimeTop 1% of 2024 papers
Abstract
In the 2024 Alzheimer's disease drug development pipeline, there are 164 clinical trials assessing 127 drugs.The 2024 Alzheimer's disease drug development pipeline has contracted compared to the 2023 Alzheimer pipeline with fewer trials, fewer drugs, and fewer new chemical entities.Drugs in the Alzheimer's disease drug development pipeline target a wide array of targets; the most common processes targeted include neurotransmitter receptors, inflammation, amyloid, and synaptic plasticity.The total development time for a potential Alzheimer's disease therapy to progress from nonclinical studies to FDA review is approximately 13 years.
Related Papers
- → Proposed Pipeline Clocking Scheme for Microarchitecture Data Propagation Delay Minimization(2020)2 cited
- An Approach to the Automated Evaluation of Pipeline Architectures in Natural Language Dialogue Systems(2011)
- Feasibility of Application of Repaired Pipeline on Surface Gathering Pipeline(2015)
- → People's Drug Guide to Deadly Drug Interactions Focuses on Drug/Drug, Drug/Food, and Drug/Vitamin Interactions(1998)
- → Inter Pipeline to expand Mid-Saskatchewan pipeline system(2014)